Effects of a Technology-Assisted Integrated Diabetes Care Program on Cardiometabolic Risk Factors Among Patients With Type 2 Diabetes in the Asia-Pacific Region

The JADE Program Randomized Clinical Trial

Lee-Ling Lim, PhD; Eric S. H. Lau, PhD; Amy W. C. Fu, MPH; Subir Ray, MD; Yi-Jun Hung, MD; Alexander T. B. Tan, MBChB; Parinya Chamnan, PhD; Wayne H. H. Sheu, PhD; Manoj S. Chawla, MD; Yook-Chin Chia, MBBS; Duc-Cong Nguyen, MD; Aravind Kesavadev, PhD; Su-Yen Goh, MBBS; Neeru Gera, MD; Thanh Huyen Vu, MD; Ronald C. W. Ma, MB Chir; Vanessa Lau, BSc; Andrea O. Y. Luk, MD; Alice P. S. Kong, MD; Juliana C. N. Chan, MD; for the Asia-Pacific JADE Study Group

Abstract

IMPORTANCE Many health care systems lack the efficiency, preparedness, or resources needed to address the increasing number of patients with type 2 diabetes, especially in low- and middle-income countries.

OBJECTIVE To examine the effects of a quality improvement intervention comprising information and communications technology and contact with nonphysician personnel on the care and cardiometabolic risk factors of patients with type 2 diabetes in 8 Asia-Pacific countries.

DESIGN, SETTING, AND PARTICIPANTS This 12-month multinational open-label randomized clinical trial was conducted from June 28, 2012, to April 28, 2016, at 50 primary care or hospital-based diabetes centers in 8 Asia-Pacific countries (India, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam). Six countries were low and middle income, and 2 countries were high income. The study was conducted in 2 phases; phase 1 enrolled 7537 participants, and phase 2 enrolled 13 297 participants. Participants in both phases were randomized on a 1:1 ratio to intervention or control groups. Data were analyzed by intention to treat and per protocol from July 3, 2019, to July 21, 2020.

INTERVENTIONS In both phases, the intervention group received 3 care components: a nurse-led Joint Asia Diabetes Evaluation (JADE) technology-guided structured evaluation, automated personalized reports to encourage patient empowerment, and 2 or more telephone or face-to-face contacts by nurses to increase patient engagement. In phase 1, the control group received the JADE technology-guided structured evaluation and automated personalized reports. In phase 2, the control group received the JADE technology-guided structured evaluation only.

MAIN OUTCOMES AND MEASURES The primary outcome was the incidence of a composite of diabetes-associated end points, including cardiovascular disease, chronic kidney disease, visual impairment or eye surgery, lower extremity amputation or foot ulcers requiring hospitalization, all-site cancers, and death. The secondary outcomes were the attainment of 2 or more primary diabetes-associated targets (glycated hemoglobin A1c <7.0%, blood pressure <130/80 mm Hg, and low-density lipoprotein cholesterol <100 mg/dL) and/or 2 or more key performance indices (reduction in glycated hemoglobin A1c ≥0.5%, reduction in systolic blood pressure ≥5 mm Hg, reduction in low-density lipoprotein cholesterol ≥19 mg/dL, and reduction in body weight ≥3.0%).

RESULTS A total of 20 834 patients with type 2 diabetes were randomized in phases 1 and 2. In phase 1, 7537 participants (mean [SD] age, 60.0 [11.3] years; 3914 men [51.9%]; 4855 patients... (continued)
Abstract (continued)

[64.4%] from low- and middle-income countries) were randomized, with 3732 patients allocated to the intervention group and 3805 patients allocated to the control group. In phase 2, 13,297 participants (mean [SD] age, 54.0 [11.1] years; 7754 men [58.3%]; 13,297 patients [100%] from low- and middle-income countries) were randomized, with 6645 patients allocated to the intervention group and 6652 patients allocated to the control group. In phase 1, compared with the control group, the intervention group had a similar risk of experiencing any of the primary outcomes (odds ratio [OR], 0.94; 95% CI, 0.74-1.21) but had an increased likelihood of attaining 2 or more primary targets (OR, 1.34; 95% CI, 1.21-1.49) and 2 or more key performance indices (OR, 1.18; 95% CI, 1.04-1.34). In phase 2, the intervention group also had a similar risk of experiencing any of the primary outcomes (OR, 1.02; 95% CI, 0.83-1.25) and had a greater likelihood of attaining 2 or more primary targets (OR, 1.25; 95% CI, 1.14-1.37) and 2 or more key performance indices (OR, 1.50; 95% CI, 1.33-1.68) compared with the control group. For attainment of 2 or more primary targets, larger effects were observed among patients in low- and middle-income countries (OR, 1.50; 95% CI, 1.29-1.74) compared with high-income countries (OR, 1.20; 95% CI, 1.03-1.39) (P = .04).

CONCLUSIONS AND RELEVANCE In this 12-month clinical trial, the use of information and communications technology and nurses to empower and engage patients did not change the number of clinical events but did reduce cardiometabolic risk factors among patients with type 2 diabetes, especially those in low- and middle-income countries in the Asia-Pacific region.

TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01631084

Introduction

Large patient volume, multiple clinical needs, and insufficient patient engagement are major barriers to translating evidence into practice among patients with type 2 diabetes who require education and continuing care. Lack of capacity is an additional challenge in low- and middle-income countries. The phenotypic heterogeneity and silent nature of type 2 diabetes can lead to delayed intervention and treatment, patient treatment nonadherence, and worse outcomes, all of which are preventable. In a meta-analysis of quality improvement interventions involving 135,112 patients with type 2 diabetes, the use of team-based care, nonphysician personnel, and information and communications technology to improve patient-practitioner communication and patient self-management skills were associated with the largest effect sizes for the reduction of cardiometabolic risk factors.

In 5 patients with type 2 diabetes, there are multiple comorbidities (eg, myocardial infarction and stroke), and these comorbidities increase the risk of cardiovascular events and death by 2-fold to 7-fold in a dose-dependent manner. Although these adverse events can be ameliorated or prevented through early detection and control of multiple risk factors, substantial care gaps exist. In high-income countries, 1 in 4 patients with type 2 diabetes is able to attain all primary diabetes-associated targets, which are conventionally defined as a glycated hemoglobin (HbA1c) level lower than 7.0% (based on measurement standards from the National Glycohemoglobin Standardization Program), a blood pressure (BP) level lower than 130/80 mm Hg, and a low-density lipoprotein (LDL) cholesterol level lower than 100 mg/dL (to convert to millimoles per liter, multiply by 0.0259). In addition, 40% to 60% of patients with type 2 diabetes in high-income countries receive organ-protective drugs. In Asia, which comprises many low- and middle-income countries, the proportion of patients with type 2 diabetes meeting all primary diabetes-associated targets has been reported to be lower than 10%, and only 30% to 40% of patients have received organ-protective drugs.
More than 60% of patients with type 2 diabetes live in Asia, with the largest populations in China and India. In these low- and middle-income countries, health care systems are often unprepared to address the increasing number of patients with type 2 diabetes, which means that many patients with type 2 diabetes are not assessed or treated, and their disease is not adequately controlled. In high-income countries, quality improvement interventions using nonphysician personnel (eg, nurses, pharmacists, dietitians, community health care workers or peer supporters, and expert patients) and information and communications technology to complement medical care have been associated with improvements in risk factors and self-management skills and reductions in diabetes-associated complications.

In 1995, we designed the Hong Kong Diabetes Register through modification of clinical setting, workflow, and team structure and used the data collected to stratify risk, empower patients, and help physicians identify care gaps. As part of health care policy reform in 2000, this care model was translated into a territory-wide risk assessment and management program, which helped to reduce mortality rates by 50% to 70% among patients with type 2 diabetes between 2001 and 2016. We used data from the Hong Kong Diabetes Register to develop equations and risk categories to estimate complications. In 2007, we developed the Joint Asia Diabetes Evaluation (JADE) technology, consisting of a web-based multifunctional multilingual portal that incorporated protocols and risk engines to guide data collection. The data formed the basis of clinic-based registers for quality assurance and were used to issue the JADE personalized reports with the aim of empowering patients and promoting shared decision-making.

Few quality improvement interventions are available for patients with type 2 diabetes in Asia despite the substantial disease burden. We hypothesized that the use of trained nurses, who were supervised by physicians and guided by the JADE technology to evaluate, empower, and engage patients, would reduce diabetes-associated complications and improve cardiometabolic risk factors among patients with type 2 diabetes in the Asia-Pacific region.

**Methods**

**Study Design**

The JADE program was designed, implemented, and coordinated (with ongoing evaluation) by the Asia Diabetes Foundation (ADF), a nonprofit research organization governed by the Chinese University of Hong Kong Foundation. From June 28, 2012, to April 28, 2016, we conducted a 12-month randomized clinical trial of a quality improvement intervention at 50 sites across 8 countries in Asia (India, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam). The study protocol was approved by the joint research ethics committee of the Chinese University of Hong Kong–New Territories East Cluster Clinical Research Ethics Committee and local institutional review boards (the trial protocol is available in Supplement 1). All patients provided written informed consent before enrollment. This study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline for randomized clinical trials.

Adult patients (aged ≥18 years) with type 2 diabetes who were receiving treatment with lifestyle modification programs and/or any glucose-lowering drugs, including insulin, were eligible. Patients with type 1 diabetes (defined as acute presentation with diabetic ketoacidosis, heavy ketonuria [blood ketone level >3], or continuous insulin requirements within 1 year of diagnosis), mental disorders, and life-threatening illnesses were excluded. The first patient visit occurred in June 2012, and the last patient visit occurred in April 2016.

**Patients and Procedures**

The JADE technology consists of a web-based portal that contains templates for guiding structured evaluation workflow, clinical decision support, and evidence-based care protocol. The JADE portal facilitates the structured collection of clinical and biochemical data to stratify patients into 1 of 4 distinct risk categories (from low risk to very high risk) for estimating cardiovascular-kidney events.
and all-cause mortality. The JADE report (eFigure 1 in Supplement 2) displays the 5-year probability of first cardiovascular-kidney events and patterns or targets of risk factors, with tailored recommendations for patients (e.g., self-management skills and treatment adherence) and health care professionals (e.g., treatment intensification, referral for education, and follow-up schedule). The JADE reports are available in 8 languages (English, traditional Chinese, simplified Chinese, Indonesian, Korean, Malay, Thai, and Vietnamese).

All participating physicians and nurses attended a 1½-day training workshop conducted by the ADF, during which they were informed about the study objectives and design. The training workshop included lectures, demonstrations, and role-play exercises. Physicians were advised to provide a dedicated workspace, located away from the busiest sections of their clinics, that ensured access to basic tools and office equipment for the nurses to implement the quality improvement intervention. By changing the setting in which the intervention occurred, nurses were in a better position to engage patients.

Patients were first scheduled for a structured evaluation session, in which the nurses used structured care report forms to collect relevant information (e.g., sociodemographic characteristics, medication receipt, and lifestyle factors), perform physical assessments (e.g., BP levels, anthropometric measurements, and 12-lead electrocardiographic examinations), conduct foot and eye examinations (e.g., 10-g monofilament testing, graduated tuning fork testing, and retinal photography, if available), and collect blood and urine samples. If uncertain about any aspect of the evaluation process, the nurses could seek medical support to complete the clinical details. Physicians were encouraged to record important information on medical history and physical examination findings (e.g., results of foot pulse and eye examinations if Doppler scans or referrals to ophthalmologists were not routine practices).

Nurses entered all anonymized data into the JADE portal, issued the personalized reports, explained the reports to patients, and returned telephone calls to patients as needed. Both physicians and nurses were trained to interpret and provide individualized explanations of the JADE report to empower patients and facilitate early intervention. Nurses could contact the physicians for any problems requiring medical attention that were detected during these sessions.

Each site was given access to the JADE portal to guide nurses in performing structured evaluations, using the JADE report to empower patients, and engaging patients with 2 or more telephone reminders or face-to-face contacts. For the nurse engagement component, nurses provided feedback to patients regarding their levels of risk factor control, encouraged patients to clarify uncertain areas (e.g., lifestyle, medications, and emotions), empowered patients with skills for self-management, and provided psychological support to help patients develop the confidence to attain multiple treatment targets. After overnight fasting, all patients received a structured evaluation at baseline and at 12 months in addition to usual care.

Randomization and Blinding

The study comprised 2 phases; phase 1 was conducted from June 2012 to August 2015, and phase 2 was conducted from June 2012 to April 2016. In both phases, the intervention group received 3 care components: a nurse-led JADE technology–guided structured evaluation, automated personalized reports to encourage patient empowerment, and 2 or more telephone reminders or face-to-face contacts by nurses to increase patient engagement. During phase 1, the control group received the JADE technology–guided structured evaluation and automated personalized reports. During phase 2, the control group received the JADE technology–guided structured evaluation only.

In phase 1, patients from 6 countries (India, Malaysia, Singapore, Taiwan, Thailand, and Vietnam) were randomized to either the intervention or control group on a 1:1 ratio using computer-generated codes kept in sealed and opaque envelopes, which were prepared by the ADF for each site. An independent on-site staff member opened the envelopes and informed participants of their group assignment. Given the study’s pragmatic design, participating patients, physicians, and nurses...
were not blinded to patients' group assignments (CONSORT diagram for phase 1 is shown in Figure 1).

During the performance of the study, results from similar studies in Hong Kong and China emerged, indicating that the personalized JADE report was associated with substantial improvements in risk factors and attenuation of between-group differences. Therefore, in phase 2, patients from 4 countries (India, Indonesia, Malaysia, and the Philippines) who were randomized to the control group received technology-guided structured evaluations but did not receive personalized JADE reports (CONSORT diagram for phase 2 is shown in Figure 2).

To optimize implementation fidelity, the ADF conducted online site monitoring using the JADE portal. After the training workshop, each site was given an operating manual with step-by-step instructions on evaluating patients, using the JADE portal to collect data and issue personalized reports, and explaining the personalized JADE reports to patients. The manual also contained questions frequently asked by patients, with sample answers for physicians and nurses to reference. To keep the study teams engaged, the ADF issued progress reports and project newsletters every 3 to 6 months, which included information on recruitment status and data completeness by site and country and provided reminders regarding all study procedures.

Outcomes

The primary outcome was the incidence of a composite of diabetes-associated end points, including cardiovascular disease, chronic kidney disease (defined as an estimated glomerular filtration rate of <60 mL/min/1.73 m²) or end-stage kidney disease (defined as the receipt of dialysis or an estimated glomerular filtration rate of <15 mL/min/1.73 m²), visual impairment or eye surgery, lower extremity amputation or foot ulcers requiring hospitalization, all-site cancers, and death. Secondary outcomes were the attainment of 2 or more primary diabetes-associated targets (HbA₁c <7.0%, BP <130/80 mm Hg, and LDL cholesterol <100 mg/dL) and/or the attainment of 2 or more key performance indices (reduction in HbA₁c ≥0.5%, reduction in systolic BP ≥5 mm Hg, reduction in LDL cholesterol ≥19 mg/dL, and reduction in body weight ≥3.0%). Sustained reduction of these cardiometabolic risk factors has been associated with decreases in the risk of cardiovascular-kidney events and

Figure 1. CONSORT Diagram for Phase 1 Study

![CONSORT Diagram for Phase 1 Study](image-url)
death.\textsuperscript{21} Patients who did not have a 12-month second evaluation by 3 months before or after their prespecified date were considered to be lost to follow-up.

**Sample Size Calculation**

In a previous 12-month pilot project, we randomized, on a 1:1 ratio, 240 patients with type 2 diabetes who had a history of ischemic heart disease or multiple risk factors. Patients received a JADE-assisted evaluation followed by allocation to either a control group, which received usual care, or an intervention group, which received additional nurse visits every 2 to 3 months at the Prince of Wales Hospital Diabetes Centre in Hong Kong.\textsuperscript{22} The proportion of patients in the intervention group who attained 2 or more primary targets increased 2.5-fold (from 15% at baseline to 37% at 12 months) compared with patients in the control group, for which the proportion increased 1.8-fold (from 15% at baseline to 27% at 12 months). Consistent with these findings, another multicenter randomized clinical trial (Effects of Structured vs Usual Care on Renal Endpoint in Type 2 Diabetes [SURE]) involving 205 patients with type 2 diabetes and chronic kidney disease reported that structured care delivered by a physician-nurse team improved the attainment of multiple targets by 2-fold (61%) compared with usual care (28%).\textsuperscript{23}

A review of the literature indicated that 12% to 36% of patients with type 2 diabetes attained 2 or more primary targets.\textsuperscript{11,24,25} Based on previous studies,\textsuperscript{11,24,25} we anticipated that treatment target attainment would increase by 50% in the control group and 2-fold in the intervention group. Assuming a default rate of 20%, a sample of 295 to 1814 patients per site would provide 80% power at a 5% significance level to confirm the benefits of the JADE-assisted multicomponent care in attaining 2 or more primary targets, depending on baseline proportions. Based on our experience, a nurse is generally able to evaluate 4 patients every morning. With access to basic facilities (eg, consultation room, telephone, and assessment tools) and physician supervision, we estimated that a full-time nurse could enroll 600 patients, perform 2 technology-guided evaluations per patient at baseline and 12 months, and provide additional patient support via face-to-face or telephone consultations (1 hour per patient) in the intervention group (n = 300). We therefore provided each site with a grant equivalent to a nurse’s salary for 18 months to facilitate implementation of the

---

**Figure 2. CONSORT Diagram for Phase 2 Study**

- 17612 Patients assessed for eligibility
- 4315 Excluded
  - 2422 Did not meet inclusion criteria
  - 1893 Declined participation
- 13297 Randomized
  - 6645 Randomized to intervention
    - 6645 Received intervention as randomized (E1, E2, and E3)
    - 1852 Lost to follow-up (received ≥12 mo of observation but did not return for evaluation)
    - 2669 Discontinued intervention (received <12 mo of observation)
    - 6645 Analyzed
      - 6645 Included in intention-to-treat analysis
      - 2124 Included in per-protocol analysis
  - 6652 Randomized to control
    - 6652 Received intervention as randomized (E1)
    - 2022 Lost to follow-up (received ≥12 mo of observation but did not return for evaluation)
    - 2853 Discontinued intervention (received <12 mo of observation)
    - 6652 Analyzed
      - 6652 Included in intention-to-treat analysis
      - 1777 Included in per-protocol analysis

E1 indicates structured evaluation (standardized data collection, physical assessment, foot and eye examinations, and laboratory measurements) guided by web-based Joint Asia Diabetes Evaluation technology; E2, automated personalized reports to encourage patient empowerment; and E3, 2 or more telephone or face-to-face contacts by nurses to increase patient engagement over a 12-month period.
quality improvement intervention. We overrecruited participants to provide sufficient power for each site to perform its own analysis after the primary analysis was completed.

**Statistical Analysis**
We conducted both intention-to-treat and per-protocol analyses. All randomized patients were included in the intention-to-treat analysis. Patients who received at least 12 months of observation and returned for a follow-up evaluation at 12 months were included in the per-protocol analysis. Multiple imputations were performed using the predictive mean matching method for handling missing data. All data were expressed as means with SDs, medians with interquartile ranges (IQRs), and numbers with percentages, as appropriate. For between-group comparisons, we used χ² tests or Fisher exact tests for categorical variables and unpaired independent t tests or Wilcoxon rank sum tests for continuous variables.

Logistic regression analyses, adjusted for country, were used to examine the effects of the intervention on primary and secondary outcomes compared with the control conditions. Patients with a documented history of any event of interest were excluded from the logistic regression models assessing the primary outcome. For secondary outcomes, all randomized patients were included in the logistic regression models. The adjusted effect estimates were presented as odds ratios (ORs) with 95% CIs. The phase 1 study included sites from low-, middle-, and high-income countries, and the phase 2 study included sites from low- and middle-income countries only. In the phase 1 study, we tested interaction between the intervention group (yes or no) and low- and middle-income countries (yes or no) using logistic regression models followed by stratified analyses. All analyses were performed using R software, version 3.6.3 (R Foundation for Statistical Computing), with a 2-tailed significance threshold of P < .05. Data were analyzed from July 3, 2019, to July 21, 2020.

**Results**

**Study Population**
From 2012 to 2015, 20,834 patients with type 2 diabetes were recruited in both phases. In phase 1, 7537 patients were randomized, with 3732 patients randomized to the intervention group and 3805 patients randomized to the control group (Figure 1). In phase 2, 13,297 patients were randomized, with 6,645 patients randomized to the intervention group and 6,652 patients randomized to the control group (Figure 2). The per-protocol analyses, which included patients with at least 12 months of observation who returned for a second evaluation at 12 months, comprised 4,514 patients in phase 1 and 3,901 patients in phase 2.

**Baseline Characteristics**
The Table shows the baseline characteristics of all randomized patients in the phase 1 and phase 2 studies. Among 7537 randomized participants in phase 1, the mean (SD) age was 60.0 (11.3) years, 3914 patients (51.9%) were male, 4855 patients (64.4%) were from low- and middle-income countries, the median duration of type 2 diabetes was 10 years (IQR, 5-15 years), and the mean (SD) HbA₁c was 7.85% (1.71%). A total of 1,177 patients (15.6%) had cardiovascular disease, and 1,322 patients (17.5%) had chronic kidney disease; 3,816 patients (50.6%) were receiving statin medications, and 3,292 patients (43.7%) were receiving renin-angiotensin system inhibitors. In total, 2,405 patients (31.9%) had already attained 2 or more primary targets at baseline.

Among 13,297 participants randomized in phase 2, the mean (SD) age was 54.0 (11.1) years, 7,754 patients (58.3%) were male, 13,297 patients (100%) were from low- and middle-income countries, the median duration of type 2 diabetes was 7 years (IQR, 3-13 years), and the mean (SD) HbA₁c was 8.39% (1.88%). A total of 3,987 patients (30.0%) were receiving statin medications, and 3,327 patients (25.0%) were receiving renin-angiotensin system inhibitors. Only 2,796 patients (21.0%) had already attained 2 or more primary targets at baseline.
Outcomes
In the phase 1 study, at 12 months, the risk of experiencing any of the diabetes-associated end points was similar between the intervention and control groups in both the intention-to-treat (OR, 0.94; 95% CI, 0.74-1.21) and per-protocol (OR, 0.95; 95% CI, 0.73-1.24) analyses after adjusting for country

Table. Baseline Characteristics of Participants in Phase 1 and Phase 2 Studies

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Phase 1 (n = 7537)*</th>
<th>Control group</th>
<th>Phase 2 (n = 13 297)b</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total participants, No.</td>
<td>3732</td>
<td>3805</td>
<td>6645</td>
<td>6652</td>
</tr>
<tr>
<td>Age, mean (SD), y</td>
<td>60.0 (11.2)</td>
<td>59.9 (11.4)</td>
<td>54.0 (11.2)</td>
<td>54.2 (11.2)</td>
</tr>
<tr>
<td>Duration of diabetes, median (IQR), y</td>
<td>9 (5-15)</td>
<td>10 (5-15)</td>
<td>7 (3-13)</td>
<td>7 (3-13)</td>
</tr>
<tr>
<td>Male sex</td>
<td>1946 (52.1)</td>
<td>1968 (51.7)</td>
<td>3869 (58.2)</td>
<td>3885 (58.4)</td>
</tr>
<tr>
<td>Female sex</td>
<td>1786 (47.9)</td>
<td>1837 (49.1)</td>
<td>2776 (41.8)</td>
<td>2767 (41.6)</td>
</tr>
<tr>
<td>National income levelc</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>1339 (35.9)</td>
<td>1343 (35.3)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Upper middle</td>
<td>599 (16.1)</td>
<td>594 (15.6)</td>
<td>250 (3.8)</td>
<td>283 (4.3)</td>
</tr>
<tr>
<td>Lower middle</td>
<td>1794 (48.1)</td>
<td>1868 (49.1)</td>
<td>6395 (96.2)</td>
<td>6369 (95.7)</td>
</tr>
<tr>
<td>≥College educational level</td>
<td>1509 (40.4)</td>
<td>1405 (36.9)</td>
<td>3244 (88.8)</td>
<td>3226 (48.5)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>336 (9.0)</td>
<td>365 (9.6)</td>
<td>631 (9.5)</td>
<td>615 (9.2)</td>
</tr>
<tr>
<td>HbA1c, mean (SD), %d</td>
<td>7.81 (1.67)</td>
<td>7.86 (1.74)</td>
<td>8.44 (1.89)</td>
<td>8.37 (1.86)</td>
</tr>
<tr>
<td>BP, mean (SD), mm Hg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>133.6 (17.2)</td>
<td>131.4 (16.9)</td>
<td>129.9 (15.5)</td>
<td>130.0 (15.7)</td>
</tr>
<tr>
<td>Diastolic</td>
<td>79.1 (9.2)</td>
<td>78.9 (9.4)</td>
<td>80.1 (8.5)</td>
<td>80.1 (8.5)</td>
</tr>
<tr>
<td>Cholesterol, mean (SD), mg/dL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>173.63 (42.54)</td>
<td>174.40 (42.92)</td>
<td>179.04 (47.56)</td>
<td>179.82 (43.70)</td>
</tr>
<tr>
<td>LDL</td>
<td>97.45 (39.06)</td>
<td>99.00 (40.60)</td>
<td>102.09 (41.76)</td>
<td>104.02 (46.02)</td>
</tr>
<tr>
<td>HDL</td>
<td>44.86 (13.92)</td>
<td>44.86 (15.47)</td>
<td>42.92 (15.08)</td>
<td>43.31 (15.85)</td>
</tr>
<tr>
<td>Triglycerides, median (IQR), mg/dL</td>
<td>133.64 (95.58-187.62)</td>
<td>132.75 (94.70-186.74)</td>
<td>146.03 (110.63-190.28)</td>
<td>145.14 (109.74-190.28)</td>
</tr>
<tr>
<td>BMI, mean (SD)</td>
<td>26.4 (4.5)</td>
<td>26.4 (4.7)</td>
<td>27.5 (4.8)</td>
<td>27.4 (4.9)</td>
</tr>
<tr>
<td>Estimated GFR, mean (SD), mL/min/1.73 m²</td>
<td>81.0 (22.9)</td>
<td>81.4 (23.3)</td>
<td>83.5 (22.4)</td>
<td>83.4 (22.4)</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>650 (17.4)</td>
<td>672 (17.7)</td>
<td>809 (12.2)</td>
<td>822 (12.4)</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>591 (15.8)</td>
<td>586 (15.4)</td>
<td>898 (13.5)</td>
<td>829 (12.5)</td>
</tr>
<tr>
<td>Medications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renin-angiotensin system inhibitors</td>
<td>1633 (43.8)</td>
<td>1659 (43.6)</td>
<td>1641 (24.7)</td>
<td>1686 (25.3)</td>
</tr>
<tr>
<td>Statins</td>
<td>1929 (51.7)</td>
<td>1887 (49.6)</td>
<td>2004 (30.2)</td>
<td>1983 (29.8)</td>
</tr>
<tr>
<td>Oral glucose-lowering drugs</td>
<td>3118 (83.5)</td>
<td>3169 (83.3)</td>
<td>5886 (88.6)</td>
<td>5836 (87.7)</td>
</tr>
<tr>
<td>Insulin</td>
<td>919 (24.6)</td>
<td>1019 (26.8)</td>
<td>1869 (28.1)</td>
<td>1742 (26.2)</td>
</tr>
<tr>
<td>Primary targets</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c, &lt;7.0%</td>
<td>1277 (34.2)</td>
<td>1284 (33.7)</td>
<td>1325 (19.9)</td>
<td>1367 (20.6)</td>
</tr>
<tr>
<td>BP &lt;130/80 mm Hg</td>
<td>867 (23.2)</td>
<td>895 (23.5)</td>
<td>1352 (20.3)</td>
<td>1381 (20.8)</td>
</tr>
<tr>
<td>LDL cholesterol &lt;100 mg/dL</td>
<td>2100 (56.3)</td>
<td>2090 (54.9)</td>
<td>3184 (47.9)</td>
<td>3077 (46.3)</td>
</tr>
<tr>
<td>≥2 Primary targets attained</td>
<td>1222 (32.7)</td>
<td>1183 (31.1)</td>
<td>1396 (21.0)</td>
<td>1400 (21.0)</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BP, blood pressure; GFR, glomerular filtration rate; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; IQR, interquartile range; JADE, Joint Asia Diabetes Evaluation; LDL, low-density lipoprotein.

SI conversion factors: To convert LDL cholesterol to millimoles per liter, multiply by 0.0259; and triglycerides to millimoles per liter, multiply by 0.0113.

* Phase 1 was conducted from June 2012 to August 2015 in 6 countries (India, Malaysia, Singapore, Taiwan, Thailand, and Vietnam). The intervention group received structured evaluation guided by web-based JADE technology, automated personalized reports for empowerment, and 2 or more telephone or face-to-face contacts by nurses over a 12-month period. The control group received structured evaluation guided by web-based JADE technology only.

b Phase 2 was conducted from June 2012 to April 2016 in 4 countries (India, Indonesia, Malaysia, and the Philippines). The intervention group received structured evaluation guided by web-based JADE technology, automated personalized reports for empowerment, and 2 or more telephone or face-to-face contacts by nurses over a 12-month period. The control group received structured evaluation guided by web-based JADE technology only.

c Based on 2019 World Bank income categories.27

d Based on measurement standards from the National Glycohemoglobin Standardization Program.10
In the intention-to-treat analysis, the intervention group had an increased likelihood of attaining 2 or more primary targets (OR, 1.34; 95% CI, 1.21-1.49) and 2 or more key performance indices (OR, 1.18; 95% CI, 1.04-1.34) compared with the control group (eTable 1 in Supplement 2).

Although similar, the effects were not statistically significant in the per-protocol analysis. Among the primary targets, the effect of the intervention on LDL cholesterol levels (ie, reducing LDL cholesterol <100 mg/dL) was consistent in both the intention-to-treat (OR, 1.17; 95% CI, 1.02-1.33) and per-protocol (OR, 1.22; 95% CI, 1.08-1.39) analyses (Figure 3). When stratified by national income level, compared with high-income countries, low- and middle-income countries had an increased likelihood of attaining 2 or more primary targets (OR, 1.50 [95% CI, 1.29-1.74] vs 1.20 [95% CI, 1.03-1.39], respectively; P = .04) and 2 or more key performance indices (OR, 1.62 [95% CI, 1.35-1.94] vs 0.86 [95% CI, 0.72-1.03], respectively; P < .001) (eFigure 2 in Supplement 2).

In the phase 2 study, the risk of experiencing any of the diabetes-associated end points was similar between the intervention and control groups in the intention-to-treat analysis (OR, 1.02; 95% CI, 0.83-1.25) (Figure 4). In the intention-to-treat analysis, the intervention group had an increased likelihood of attaining 2 or more primary targets (OR, 1.25; 95% CI, 1.14-1.37) and 2 or more key performance indices (OR, 1.50; 95% CI, 1.33-1.68) compared with the control group (eTable 1 in Supplement 2). In the per-protocol analysis, the effect of the intervention on the attainment of 2 or more key performance indices remained significant (OR, 1.29; 95% CI, 1.13-1.47) but was not significant for the attainment of 2 or more primary targets (OR, 0.93; 95% CI, 0.82-1.06). Both the intention-to-treat and per-protocol analyses showed consistent results for the primary target of

Figure 3. Effects of Intervention vs Control Conditions on Cardiometabolic Risk Factors Among Participants in Phase 1 Study

### A: Intention-to-treat population

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Patients, No.</th>
<th>OR (95% CI)</th>
<th>Favors lower risk</th>
<th>Favors higher risk</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All diabetes-associated end points</td>
<td>4747</td>
<td>0.94 (0.74-1.21)</td>
<td></td>
<td></td>
<td>.65</td>
</tr>
<tr>
<td>≥2 Primary targets attained</td>
<td>7537</td>
<td>1.34 (1.21-1.49)</td>
<td></td>
<td></td>
<td>&lt;.001</td>
</tr>
<tr>
<td>HbA1c &lt;7.0%</td>
<td>7537</td>
<td>1.07 (0.95-1.21)</td>
<td></td>
<td></td>
<td>.27</td>
</tr>
<tr>
<td>BP &lt;130/80 mm Hg</td>
<td>7537</td>
<td>1.03 (0.91-1.17)</td>
<td></td>
<td></td>
<td>.60</td>
</tr>
<tr>
<td>LDL cholesterol &lt;100 mg/dL</td>
<td>7537</td>
<td>1.17 (1.02-1.33)</td>
<td></td>
<td></td>
<td>.02</td>
</tr>
<tr>
<td>≥2 Key performance indices attained</td>
<td>7537</td>
<td>1.18 (1.04-1.34)</td>
<td></td>
<td></td>
<td>.01</td>
</tr>
<tr>
<td>HbA1c reduction ≥5%</td>
<td>7537</td>
<td>1.07 (0.95-1.21)</td>
<td></td>
<td></td>
<td>.26</td>
</tr>
<tr>
<td>Systolic BP reduction ≥5 mm Hg</td>
<td>7537</td>
<td>1.03 (0.90-1.13)</td>
<td></td>
<td></td>
<td>.92</td>
</tr>
<tr>
<td>LDL cholesterol reduction ≥19 mg/dL</td>
<td>7537</td>
<td>1.06 (0.93-1.22)</td>
<td></td>
<td></td>
<td>.38</td>
</tr>
<tr>
<td>Body weight reduction ≥3.0%</td>
<td>7537</td>
<td>1.05 (0.92-1.21)</td>
<td></td>
<td></td>
<td>.46</td>
</tr>
</tbody>
</table>

### B: Per-protocol population

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Patients, No.</th>
<th>OR (95% CI)</th>
<th>Favors lower risk</th>
<th>Favors higher risk</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All diabetes-associated end points</td>
<td>2559</td>
<td>0.95 (0.73-1.24)</td>
<td></td>
<td></td>
<td>.71</td>
</tr>
<tr>
<td>≥2 Primary targets attained</td>
<td>4514</td>
<td>1.10 (0.97-1.24)</td>
<td></td>
<td></td>
<td>.13</td>
</tr>
<tr>
<td>HbA1c &lt;7.0%</td>
<td>4512</td>
<td>1.07 (0.95-1.20)</td>
<td></td>
<td></td>
<td>.28</td>
</tr>
<tr>
<td>BP &lt;130/80 mm Hg</td>
<td>4514</td>
<td>1.08 (0.94-1.23)</td>
<td></td>
<td></td>
<td>.27</td>
</tr>
<tr>
<td>LDL cholesterol &lt;100 mg/dL</td>
<td>4465</td>
<td>1.22 (1.08-1.39)</td>
<td></td>
<td></td>
<td>.002</td>
</tr>
<tr>
<td>≥2 Key performance indices attained</td>
<td>4514</td>
<td>1.05 (0.92-1.20)</td>
<td></td>
<td></td>
<td>.48</td>
</tr>
<tr>
<td>HbA1c reduction ≥5%</td>
<td>4477</td>
<td>1.10 (0.97-1.26)</td>
<td></td>
<td></td>
<td>.14</td>
</tr>
<tr>
<td>Systolic BP reduction ≥5 mm Hg</td>
<td>4497</td>
<td>1.02 (0.90-1.16)</td>
<td></td>
<td></td>
<td>.73</td>
</tr>
<tr>
<td>LDL cholesterol reduction ≥19 mg/dL</td>
<td>4369</td>
<td>1.12 (0.97-1.30)</td>
<td></td>
<td></td>
<td>.12</td>
</tr>
<tr>
<td>Body weight reduction ≥3.0%</td>
<td>4488</td>
<td>1.05 (0.89-1.22)</td>
<td></td>
<td></td>
<td>.58</td>
</tr>
</tbody>
</table>

To convert low-density lipoprotein (LDL) cholesterol from milligrams per deciliter to millimoles per liter, multiply by 0.0259. HbA1c indicates glycated hemoglobin A1c; BP, blood pressure; OR, odds ratio.

---

To convert low-density lipoprotein (LDL) cholesterol from milligrams per deciliter to millimoles per liter, multiply by 0.0259. HbA1c indicates glycated hemoglobin A1c; BP, blood pressure; OR, odds ratio.

---

To convert low-density lipoprotein (LDL) cholesterol from milligrams per deciliter to millimoles per liter, multiply by 0.0259. HbA1c indicates glycated hemoglobin A1c; BP, blood pressure; OR, odds ratio.

---

To convert low-density lipoprotein (LDL) cholesterol from milligrams per deciliter to millimoles per liter, multiply by 0.0259. HbA1c indicates glycated hemoglobin A1c; BP, blood pressure; OR, odds ratio.

---

To convert low-density lipoprotein (LDL) cholesterol from milligrams per deciliter to millimoles per liter, multiply by 0.0259. HbA1c indicates glycated hemoglobin A1c; BP, blood pressure; OR, odds ratio.

---

To convert low-density lipoprotein (LDL) cholesterol from milligrams per deciliter to millimoles per liter, multiply by 0.0259. HbA1c indicates glycated hemoglobin A1c; BP, blood pressure; OR, odds ratio.

---

To convert low-density lipoprotein (LDL) cholesterol from milligrams per deciliter to millimoles per liter, multiply by 0.0259. HbA1c indicates glycated hemoglobin A1c; BP, blood pressure; OR, odds ratio.

---

To convert low-density lipoprotein (LDL) cholesterol from milligrams per deciliter to millimoles per liter, multiply by 0.0259. HbA1c indicates glycated hemoglobin A1c; BP, blood pressure; OR, odds ratio.

---

To convert low-density lipoprotein (LDL) cholesterol from milligrams per deciliter to millimoles per liter, multiply by 0.0259. HbA1c indicates glycated hemoglobin A1c; BP, blood pressure; OR, odds ratio.
attaining an LDL cholesterol level of below 100 mg/dL and the key performance indices of reducing HbA₁c level by 0.5% or more and reducing LDL cholesterol level by 19 mg/dL or more (Figure 4).

Among those who had at least 12 months of observation, 2596 patients (34.4%) in phase 1 and 3874 patients (29.1%) in phase 2 did not return for a structured evaluation. A total of 4514 patients (59.9%) in phase 1 and 3901 patients (29.3%) in phase 2 returned for a structured evaluation after at least 12 months of observation. In the phase 1 study, patients who returned for evaluation were older, had longer disease duration, had greater frequency of a history of cardiovascular disease or chronic kidney disease, had higher medication receipt (with the exception of insulin), and had higher target attainment at baseline compared with patients who did not return for evaluation (eTable 2 in Supplement 2). Similar characteristics were observed among participants in the phase 2 study (eTable 3 in Supplement 2).

Discussion

In this 12-month multinational randomized clinical trial of a quality improvement intervention, a multicomponent program using trained nurses under physician supervision and assistance from the JADE technology to evaluate, empower, and engage patients did not alter the number of clinical events among Asian patients with type 2 diabetes compared with the control group. However, the intervention group was more likely to attain multiple treatment targets and experienced clinically meaningful reductions in cardiometabolic risk factors, with greater effect sizes among participants in

Figure 4. Effects of Intervention vs Control Conditions on Cardiometabolic Risk Factors Among Participants in Phase 2 Study

To convert low-density lipoprotein (LDL) cholesterol from milligrams per deciliter to millimoles per liter, multiply by 0.0259. HbA₁c indicates glycated hemoglobin A₁c; BP, blood pressure; OR, odds ratio.
low- and middle-income countries compared with high-income countries. Despite the diverse care settings, results from this study support the use of information and communications technology and nonphysician personnel to decrease care gaps among patients with type 2 diabetes. This quality improvement intervention focused on the transfer of knowledge to promote self-management skills, treatment adherence, and improvements in ongoing care. Nurses provided an important means of relaying information between physicians and patients to ensure data were collected, documented, and communicated to promote shared decision-making.

Because of the relatively brief follow-up period, we were not able to demonstrate differences in clinical events because the effects of multiple risk factor reduction will likely take years to emerge. In Hong Kong, after a median follow-up of 4.5 to 6.0 years, the implementation of a similar risk assessment and management program complemented by a patient empowerment program in primary and secondary care settings was associated with a 30% to 60% reduction in the risk of cardiovascular-kidney events and death. In previous randomized clinical trials (such as the Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria [Steno-2] study, the Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases [J-DOIT3], and the SURE study, which were characterized by the use of protocols, care coordinators, standardized data collection, and access to essential medications), marked improvement in clinical outcomes was observed, even among participants in the control groups.

In the present study, by training nurses to perform the JADE technology-guided structured evaluations, we observed reductions in multiple risk factors after 12 months, supporting the notion that the provision of structured care using information and communications technology and nonphysician personnel can facilitate systematic data collection to change actions in care delivery. By using personalized reports to explain these data to patients together with nurse reminders to empower and engage patients, this quality improvement intervention resulted in a greater likelihood of clinically meaningful reductions in systolic BP (≥5 mm Hg), HbA1c (≥0.5%), LDL cholesterol (≥19 mg/dL), and/or body weight (≥3.0%) among the intervention group. These improvements, if sustained, may lead to reductions in cardiovascular-kidney events and death.

In the phase 1 study, all patients received the personalized JADE reports that were written in everyday language. This empowerment component might have attenuated the benefits of the additional nurse contacts, which were designed to engage patients and reinforce self-management skills. In the phase 2 study, the control condition represented a more accurate real-world situation, in which patients are often not informed of the results of their evaluations, especially if they reside in low- and middle-income countries that have scarce health care resources and limited time available for patient-practitioner consultations. It was also in these low- and middle-income countries where the effect of our intervention was most evident. Because of the low physician-to-patient ratio in low- and middle-income countries, a heavy workload often produces care fragmentation, patient treatment nonadherence, and burnout among health care professionals. The present study attempted to reduce the heavy workload of physicians by providing funding to hire a nurse and the JADE technology with built-in protocols and decision support, which could be used to train nursing staff to complement medical care. However, because of the high default rate, brief follow-up duration, overestimation of effect size, and other unforeseen factors, we were not able to confirm the primary outcome of clinical events. These unforeseen factors included staffing changes, insufficient capacity, lack of financial coverage for structured evaluations and medications, lack of patient literacy and readiness to receive care from nonphysician personnel, and lack of institutional support. Despite these challenges, the reduction of multiple risk factors supported our hypothesis that the use of nonphysician personnel, guided by information and communications technology, was able to decrease care gaps, especially in low- and middle-income countries. Thus, by changing the setting and empowering nurses to deliver the JADE-assisted program and facilitate communication among all parties concerned, we could start to build capacity and empower not only the patients but the health care team to deliver evidence-based integrated care.
The analyses of low-, middle-, and high-income countries were performed post hoc. The lack of infrastructure and capacity in low- and middle-income countries might have resulted in greater benefits for facilities in those countries compared with high-income countries, as the additional manpower and technology provided the necessary resources to help sites in low- and middle-income countries evaluate, empower, and engage patients. Better practice environments in high-income countries vs low- and middle-income countries might also have attenuated the differences between the intervention and control groups. The seemingly counterintuitive results indicating that the intervention was associated with a lower, albeit not statistically significant, likelihood of reducing clinical events in high-income countries might be owing to ascertainment bias, as facilities in high-income countries are better able to document events and have greater availability of laboratory tests compared with facilities in low- and middle-income countries. Despite the potential of the JADE program, a conducive macroenvironment and team alignment are as important as patient engagement to overcoming the multiple behavioral and administrative barriers to delivering high-quality diabetes care.

**Strengths and Limitations**

This study has strengths. The study was multinational and comprised a broad range of health care facilities, including hospital and community-based clinics with universal, subsidized, or private payment structures. This heterogeneity means that the study’s results are relevant to many settings.

This study also has limitations. These limitations can inform future design and implementation of pragmatic research aimed at defining and evaluating operational strategies to create change in the care of patients with type 2 diabetes. First, by its nature, the study was not blinded, and the diversity of the health care systems included might have affected implementation fidelity and default rates. This limitation was minimized by the provision of training to all physician-nurse teams, the use of standardized protocols and case record forms, and the implementation of online monitoring by the ADF, with regular site progress reports and project newsletters.

Second, the 1-year default rate observed in this clinical trial of a quality improvement intervention was higher than that in most randomized clinical trials that receive funding for on-site monitoring and compensation to patients, health care professionals, and institutions. To that end, most randomized clinical trials provide evidence of efficacy, while clinical trials of real-world interventions provide evidence of effectiveness and identify barriers and enablers for translating evidence into practice. In many low- and middle-income countries, the costs associated with structured evaluations (especially laboratory tests) and medications are paid out of pocket and not covered by health care systems. In this quality improvement intervention, we did not cover the costs for assessments and medications. Depending on the extent of subsidies, the participants’ inability or unwillingness to pay might explain the approximately 30% default rate among those scheduled to return for evaluation at 12 months. A similar default rate was reported in the China JADE Program, suggesting that these defaults are real-world occurrences. Even with close monitoring and provision of incentives to retain patients, treatment discontinuation rates as high as 25% have been reported in pharmaceutical industry-sponsored clinical trials lasting several years. Despite these challenges, the risk factor reduction associated with our multicomponent intervention remained clinically substantial in both the intention-to-treat and per-protocol analyses.

Third, volunteer bias among both the patients and participating study teams could limit the generalizability of the study’s results. Fourth, qualitative research is needed to understand the perspectives of patients, health care professionals, and payers regarding the implementation, acceptance, and adherence to quality improvement interventions such as this one, which will enable further adaptation of these interventions to address local needs. Fifth, participants who did not return for evaluation were younger and had higher educational levels but lower target attainment than those who returned for evaluation. Low levels of risk awareness, competing life priorities, and/or demand for high-quality services among younger individuals, which may result from higher
literacy, suggest a need for refinement to make this technology-enhanced team-based care model more user friendly and engaging.\textsuperscript{31,35}

Conclusions

Diabetes is a complex condition requiring multidimensional intervention to reduce multiple risk factors and prevent complications. By using a multicomponent approach that included nurse engagement as well as information and communications technology, the present intervention was able to improve the control of multiple cardiometabolic risk factors. Given the relatively low costs of the JADE program, which involved training nurses to perform annual structured evaluations guided by the JADE portal and to use personalized reports to empower patients and promote shared decision-making, this care model might provide a readily available solution, especially in low- and middle-income countries, to improve clinical outcomes among patients with type 2 diabetes pending other health care reforms.
Conflicts of Interest Disclosures: Dr Lim reported receiving personal fees from Merck Sharp & Dohme during the conduct of the study and grants from AstraZeneca; personal fees from Boehringer Ingelheim, Merck Serono, Novartis, Pfizer, Procter & Gamble Health, and Servier Laboratories; and nonfinancial support from Medtronic, Novo Nordisk, and Sanofi outside the submitted work. Ms Fu reported receiving grants from Merck Sharp & Dohme during the conduct of the study. Dr Ma reported receiving grants from AstraZeneca, Bayer, Merck Sharp & Dohme, Novo Nordisk, and Tricida and personal fees from AstraZeneca and Boehringer Ingelheim outside the submitted work. Ms V. Lau reported receiving grants from Merck Sharp & Dohme during the conduct of the study. Dr Kong reported receiving grants from AstraZeneca and personal fees from Abbott, AstraZeneca, Eli Lilly and Company, and Sanofi outside the submitted work. Dr Chan reported receiving grants from Merck Sharp & Dohme during the conduct of the study; grants from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Eli Lilly and Company, GlaxoSmithKline, Merck Serono, Pfizer, and Sanofi; and personal fees from Bristol Myers Squibb (donated to the Chinese University of Hong Kong, the American Diabetes Association, and other charity organizations to support diabetes research and education) outside the submitted work. No other disclosures were reported.

Funding/Support: This study was supported by an unrestricted educational grant from Merck Sharp & Dohme to the Asia Diabetes Foundation, a nonprofit research organization established by the Chinese University of Hong Kong Foundation.

Role of the Funder/Sponsor: The funding organization had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Asia-Pacific JADE Study Group: Dr Aggarwal's Clinic, Noida, India: Ajay Aggarwal; Care and Cure Clinic Rohini, New Delhi, India: Pankaj Aneja; Endocrine Clinic, Cuttack, India: Anoj K. Baliai; Shivajoyti Clinic, Bangalore, India: Arpan Bhattacharyya; St Frances Cabrini Medical Center, Batangas, Philippines: Cecille A Cruz; Daksha Medical and Research Centre, Coimbatore, India: Suresh Damodharan; Dr Vinay Kumar Dhandhania's Clinic, Jharkhand, India: Vinay K. Dhandhania; Mitra Kemayoran Hospital, Jakarta, Indonesia: Fatimah Eliana; Shreya Diabetes Care Centre, Mumbai, India: Pradeep Gadge; Max Super Speciality, New Delhi, India: Sujeet Jha; Delhi Diabetes Research Centre, New Delhi, India: Ashok K. Jhingan; Synergy Hospital, Indore, India: Sandeep Julla; Escorts Fortis Hospital and Research Centre, Ltd, Haryana, India: S. K. Kapoor; Diabetes Medicare Centre, Chennai, India: G. V. Kumar; Bliss Clinic, Kolkata, India: Prabir K. Kundu; Priya Nursing Home, Chennai, India: S. S. Lakshmanan; Dr Panikar's Speciality Care Centre, Mumbai, India: Vijay Panikar; The Healing Touch Clinic, Cuttack, India: Sudhiranjan Pattanaik; Notre Dame De Chretes Hospital, Baguio, Philippines: Francis Pizarro; Persahabatan Hospital, Jakarta, Indonesia: Rochsis Mandoko; Dr Mohan's Diabetes Specialities Centre, Hyderabad, India: Nadiminty G. Sastry; Gujarat Endocrine Centre, Gujarat, India: Parag R. Shah; Dr Parminder Singh's Clinic, Ludhiana, India: Parminder Singh; Dr S. K. Singh's Clinic, Varanasi, India: S. K. Singh; SS Diabetes Care Clinic, Jakarta, Indonesia: Sidartawan Soegondo; Modern Hospital, Jalandhar Punjab, India: Vijip Talwar; Care Diabetes Centre, Warangol, India: Saini Venkateshwarlu; Indraprastha Apollo Hospital, New Delhi, India: S. K. Wangnoo.

Meeting Presentations: Partial results from the study were presented as an oral abstract at the International Diabetes Federation World Diabetes Congress; December 4, 2017; Abu Dhabi, United Arab Emirates; and the International Diabetes Federation World Diabetes Congress; December 3, 2019; Busan, Korea.

Data Sharing Statement: See Supplement 3.

Additional Contributions: Gary T. C. Ko, MD, Peter C. Y. Tong, PhD, and Wing Yee So, MD, of the Department of Medicine and Therapeutics, The Chinese University of Hong Kong, and Greg Lyubomirsky, MD, of Merck Sharp & Dohme, contributed to the initiation phase of the JADE program without compensation. The authors thank the study participants; the Asia-Pacific JADE collaborators, nursing staff, and research staff at all study sites; and all staff members at the Asia Diabetes Foundation for providing administrative, technical, and material support.

REFERENCES


22. Wong RYM. A randomized study to evaluate the effectiveness of a treat to target clinic led by nurse consultant in high risk patients with type 2 diabetes. Paper presented at: 8th International Diabetes Federation Western Pacific Region Congress; October 18, 2010; Busan, Korea.


SUPPLEMENT 1.
Trial Protocol

SUPPLEMENT 2.
eFigure 1. Example of JADE Personalized Report

eFigure 2. Effects of Intervention (E1+2+3) vs Control (E1+2) on Cardiometabolic Risk Factors in Phase 1 Study, Stratified by National Income Level (Intention-to-Treat and Per-Protocol Analyses)

eTable 1. Changes in Medication Usage and the Proportion of Patients Attaining Treatment Targets and Key Performance Indices in the Intention-to-Treat Population

eTable 2. Comparison of Baseline Characteristics Between Patients With at Least 12 Months of Observation Who Did and Did Not Return for Repeat Evaluation in Phase 1 Study

eTable 3. Comparison of Baseline Characteristics Between Patients With at Least 12 Months of Observation Who Did and Did Not Return for Repeat Evaluation in Phase 2 Study

SUPPLEMENT 3.
Data Sharing Statement